



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
06/247,656	03/26/81	LUDDEKES	R 23070-107

TOWNSEND & TOWNSEND
STEINERT STREET TOWER
ONE MARKET PLAZA
SAN FRANCISCO, CA 94103

EXAMINER	
TOM GLASS	
ART UNIT	PAPER NUMBER
176	5
DATE MAILED:	

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

JAN 18 1983

This application has been examined. Responsive to communication filed on JULY 1, 1982 This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

1. Notice of References Cited by Examiner, PTO-892 2. Notice of Informal Patent Drawing, PTO-948
3. Notice of References Cited by Applicant, PTO-1449 4. Notice of Informal Patent Application, Form PTO-152

Part II SUMMARY OF ACTION

5. _____

1. Claims 1-3 are pending in the application.

Of the above, claims _____ are withdrawn from consideration.

2. Claims _____ have been cancelled.

3. Claims _____ are allowed.

4. Claims 1-3 are rejected.

5. Claims _____ are objected to.

6. Claims _____ are subject to restriction or election requirement.

7. The formal drawings filed on _____ are acceptable.

8. The drawing correction request filed on _____ has been approved. disapproved.

9. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has
 been received. not been received. been filed in parent application, serial no. _____
filed on _____.

10. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

11. Other

The disclosure is objected to as failing to provide an enabling disclosure as required by the first paragraph of 35 U.S.C. 112. This paragraph of the statute, requires that the specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The Rowland letter of April 8, 1981 and the Brandon letter of April 26, 1981 have been considered. However, the "permanent availability" has not been established. The Brandon letter indicates that the fee has not been paid and its receipt is required for the deposit to be maintained. The Rowland letter indicates that the responsibility for replacement of the deposit lies with the Regents of the University of California. However, it is not evident from the record if 1) the fee has been paid and 2) if the Board of Regents will replace the deposit. Submission of such proof would obviate this objection. Accordingly, the objection is deemed proper and repeated.

Claims 1 and 2 rejected under 35 U.S.C. 112,
first paragraph, for the reasons set forth in the
preceding paragraphs.

The claims are based on an inadequate
disclosure. Note the objection above.

Claim 3 is rejected under 35 U.S.C. 103 as
being unpatentable over Ham et al taken in view of
Kohler et al and Iscove et al. Although, the invention
is not identically disclosed or described as set forth
in section 102 of Title 35 U.S.C., the differences
between the subject matter sought to be patented and
the prior art are such that the subject matter as a
whole would have been obvious at the time the invention
was made to a person having ordinary skill in the art
to which said subject matter pertains.

The basis for this rejection was set forth in
the first office action. Applicant urges that a
thousand fold increase in fusion frequency renders the
cell line and the method of producing the cell line
unobvious. Applicant further urges unexpected results
achieved from a conventional process.

The unexpected high fusion frequency does
render the cell line unobvious since these
characteristics are inherently present in the cell
line. However, claim 3 is not limited to either one of

the two critical factors; namely, the degree of enhanced fusion frequency obtained ^{over} _{in} the particular parent cell line or the conditions responsible for the increased rate. Due to the naturally large variation in fusion frequency in various conventional cell fusions, a claim limited merely to "enhancing fusion frequency" does not sufficiently define this critical feature. Since applicant's attorney admits (page 2 line 28-29) that the mechanism is not known, and since the method has been shown to work with only one cell line, the particular cell line appears critical. Note that this method has not been shown to be repeatable, much less workable with any related cell line, even less with any human cell, and even less with cells from any animal as is so claimed. Accordingly, in the absence of these critical features or data showing widespread applicability, claim 3 appears to read on an obvious method to reduce fetal calf serum dependence with natural variations in fusion frequency as is set forth in the first office action.

Claims 1 and 2 are free of prior art.

THIS ACTION IS MADE FINAL.

J.E.TARCZA:dt
J.E.T.

11/12/82

703-557-3618

[Signature]
THOMAS G. WISEMAN
EXAMINER
CLOUD ACT UNIT